NASDAQ:ABVC

Abvc Biopharma Stock News

Healthcare > Biotechnology

Buy ABVC

*Your capital is at risk

$1.28

+0.0300 (+2.40%)

At Close: Jun 03, 2026

Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)

01:12am, Monday, 27'th Apr 2026

ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Edgewise Therapeutics (NASDAQ: EWTX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two compani

ABVC BioPharma (NASDAQ:ABVC) Stock Price Down 3.4% – Time to Sell?

02:20am, Friday, 24'th Apr 2026

ABVC BioPharma, Inc. (NASDAQ: ABVC - Get Free Report)'s stock price was down 3.4% during trading on Thursday. The stock traded as low as $1.11 and last traded at $1.14. Approximately 49,807 shares cha

ABVC BioPharma (NASDAQ:ABVC) Trading Up 11.3% – Here’s Why

01:59am, Thursday, 02'nd Apr 2026

ABVC BioPharma, Inc. (NASDAQ: ABVC - Get Free Report) shares were up 11.3% on Wednesday. The stock traded as high as $1.13 and last traded at $1.08. Approximately 141,320 shares changed hands during m

ABVC BioPharma (NASDAQ:ABVC) Trading Down 4.9% – Here’s What Happened

02:55am, Tuesday, 30'th Dec 2025

ABVC BioPharma, Inc. (NASDAQ: ABVC - Get Free Report)'s stock price was down 4.9% during mid-day trading on Monday. The stock traded as low as $2.30 and last traded at $2.31. Approximately 73,821 shar

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

06:30am, Wednesday, 11'th Dec 2024

FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervou

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

08:45am, Tuesday, 22'nd Oct 2024

FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervo

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

07:30am, Thursday, 15'th Aug 2024

• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

09:25am, Thursday, 18'th Apr 2024

FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oph

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

09:00am, Wednesday, 17'th Apr 2024

FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in opht

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

08:30am, Wednesday, 10'th Apr 2024

FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by